Takeda Pharmaceutical Company Limited logo

Takeda Pharmaceutical Company LimitedNYSE: TAK

Profile

Sector:

Healthcare

Country:

Japan

IPO:

05 January 2010

Next earnings report:

N/A

Last dividends:

27 March 2024

Next dividends:

N/A
$44.19 B
-17%vs. 3y high
98%vs. sector
-7%vs. 3y high
73%vs. sector
-18%vs. 3y high
39%vs. sector
-16%vs. 3y high
30%vs. sector

Price

after hours | Thu, 31 Oct 2024 22:26:20 GMT
$13.94+$0.03(+0.22%)
$7.75 B$7.07 M
$7.75 B$611.00 M

Analysts recommendations

Institutional Ownership

TAK Latest News

Takeda Pharmaceutical Company Limited (TAK) Q2 2025 Earnings Call Transcript
seekingalpha.com31 October 2024 Sentiment: -

Takeda Pharmaceutical Company Limited (NYSE:TAK ) Q2 2025 Earnings Call October 31, 2024 6:00 AM ET Company Participants Christopher O'Reilly - Head, Investor Relations Christophe Weber - President and Chief Executive Officer Milano Furuta - Chief Financial Officer Andy Plump - President, R&D Ramona Sequeira - President, Global Portfolio Julie Kim - President, U.S. Business Unit Giles Platford - President, PDT Business Unit Teresa Bitetti - President, Global Oncology Business Unit Conference Call Participants Steve Barker - Jefferies Mike Nedelcovych - TD Cowen Tony Ren - Macquarie Miki Sogi - Bernstein Christopher O'Reilly Thank you for taking time out of your very busy schedule to join the FY ‘24 Q2 earnings announcement by Takeda. I'm the master of ceremony, Head of IR.

Japan's Takeda returns to Q2 profit as drugmaker recovers from impairments
reuters.com31 October 2024 Sentiment: POSITIVE

Japan's Takeda Pharmaceutical returned to profitability in the second quarter following large impairment losses a year earlier and is restructuring to cut costs.

Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook
businesswire.com31 October 2024 Sentiment: POSITIVE

OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the first half of fiscal year 2024 (six months ended September 30, 2024), with continued momentum in its Growth & Launch Products driving growth. The company has upgraded its full year forecasts and Management Guidance to reflect stronger than anticipated first-half performance (including milder than anticipated generic erosion of VYVANSE® in the U.S.) and revised foreign exchange assumptions. T.

Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer
businesswire.com24 September 2024 Sentiment: POSITIVE

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that it has received approval from the Japanese Ministry of Health, Labour and Welfare to manufacture and market FRUZAQLA Capsules 1mg/5mg (generic name: fruquintinib), a selective oral inhibitor of vascular endothelial growth factor receptor (VEGFR) -1, -2 and -3, for the treatment of advanced or recurrent colorectal cancer (CRC) that is neither curable nor resectable and that has progressed after chem.

TAK vs. STVN: Which Stock Is the Better Value Option?
zacks.com17 September 2024 Sentiment: POSITIVE

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Takeda Pharmaceutical Co. (TAK) and Stevanato Group (STVN). But which of these two stocks is more attractive to value investors?

Takeda Announces First Quarter FY2024 Results - Strong Performance by Growth & Launch Products; Advancements in Promising Late-Stage Pipeline
businesswire.com31 July 2024 Sentiment: POSITIVE

OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the first quarter of fiscal year 2024 (period ended June 30, 2024), with continued momentum in its Growth & Launch Products driving Core growth at CER and more than offsetting revenue impact resulting from significant losses of exclusivity that occurred in the previous fiscal year. The strong performance of Takeda's Growth and Launch Product portfolio, which grew 17.8% at CER and represented 46%.

Takeda's AI-Powered Strategy To Optimize Operations And Accelerate Its Pipeline
seekingalpha.com19 July 2024 Sentiment: POSITIVE

Takeda Pharmaceutical Company Limited showed signs of improvement despite revenue declines in oncology and neurosciences, thanks to gains in gastrointestinal and inflammation sectors and strategic leadership changes. The company's “returning to growth program” aims to increase operating margins by 100-250 basis points annually from 2025 onwards. Despite a challenging FY2023 with a significant net profit decline, Takeda expects its AI-powered returning to growth program to improve financial stability and shareholder returns by 2025.

Takeda Announces New Assignments of Directors
businesswire.com26 June 2024 Sentiment: POSITIVE

OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) has announced new assignments of directors, determined at the Board of Directors meeting and at the Audit and Supervisory Committee meeting, following the 148th Ordinary Meeting of Shareholders, held in Osaka today. Takeda's Board of Directors has 11 members serving as external directors out of a total of 14 members, helping to ensure transparency and objectivity. An external director will continue to chair the Board of Directors. The.

Takeda To Keep Pushing for China Biotech Partnership
youtube.com25 June 2024 Sentiment: POSITIVE

Takeda Pharmaceutical will continue efforts to forge partnerships with Chinese biotech companies even with some tensions between US and China. Speaking exclusively to Bloomberg, CEO Christophe Weber said the recent US Congress effort to limit Chinese biotech's access to American market would have limited impact on Takeda's business with China.

Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies
businesswire.com24 June 2024 Sentiment: POSITIVE

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that LIVTENCITY® (maribavir) has been approved by the Japanese Ministry of Health, Labour and Welfare (MHLW) for post-transplant cytomegalovirus (CMV) infection/disease that is refractory to existing anti-CMV therapies.4 LIVTENCITY is the first and only post-transplant anti-CMV treatment approved in Japan that targets and inhibits pUL97 kinase and its natural substrates.1 “We are pleased by the approval.

  • 1(current)
  • 2
  • 3

What type of business is Takeda Pharmaceutical Company Limited?

Takeda Pharmaceutical Company Limited is a biopharmaceutical company, one of the largest in the world. The headquarters is located in Tokyo, Japan. The company was actually founded in 1781. In 1915, it was registered as Takeda. In 1998, subsidiary companies were opened in the USA and the UK. The company's research and development are focused on four areas: oncology, rare diseases, neurology, and gastroenterology. They also have R&D developments in promising areas such as plasma therapy and vaccine manufacturing. Takeda produces a wide range of pharmaceuticals. One of the main drugs produced by Takeda is a medication used for ulcerative colitis and Crohn's disease.

What sector is Takeda Pharmaceutical Company Limited in?

Takeda Pharmaceutical Company Limited is in the Healthcare sector

What industry is Takeda Pharmaceutical Company Limited in?

Takeda Pharmaceutical Company Limited is in the Drug Manufacturers - Specialty & Generic industry

What country is Takeda Pharmaceutical Company Limited from?

Takeda Pharmaceutical Company Limited is headquartered in Japan

When did Takeda Pharmaceutical Company Limited go public?

Takeda Pharmaceutical Company Limited initial public offering (IPO) was on 05 January 2010

What is Takeda Pharmaceutical Company Limited website?

https://www.takeda.com

Is Takeda Pharmaceutical Company Limited in the S&P 500?

No, Takeda Pharmaceutical Company Limited is not included in the S&P 500 index

Is Takeda Pharmaceutical Company Limited in the NASDAQ 100?

No, Takeda Pharmaceutical Company Limited is not included in the NASDAQ 100 index

Is Takeda Pharmaceutical Company Limited in the Dow Jones?

No, Takeda Pharmaceutical Company Limited is not included in the Dow Jones index

When was Takeda Pharmaceutical Company Limited the previous earnings report?

No data

When does Takeda Pharmaceutical Company Limited earnings report?

Next earnings report date is not announced yet